Not sure how to feel about this PR, especially after hours. I wasn’t expecting the trial to be stopped, but I think there was some hype that it would. We now have to wait for the interim analysis of the severe trial (Data at the end of September) to get an idea of efficacy, but we at least know it’s safe. It’ll be interesting to see how the market responds tomorrow.

It seems that uplsiting may rely on how good the M2M results are. This should be an interesting month.